HIMS Hims & Hers Health, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:23
Jul 17
Jul 17
Buy beaten-down growth names IREN, HIMS, ONDS, ASTS, KRKNF, and OUST on a mean-reversion thesis; speaker expects a sharp V-shaped bounce after recent month-long selloff, though no specific catalyst or fundamental trigger is cited.
MED
09:09
Jul 16
Jul 16
The author lists HIMS, GOOGL, and MRVL as the tickers with the least chance of hitting previous price targets, based on current reading, without stating a personal position.
LOW
07:47
Jul 16
Jul 16
Upcoming FDA advisory committee review of peptide compounding is a potential catalyst for HIMS, but the recommendation is advisory and the tweet states no explicit buy, ownership, or position.
HIGH
20:59
Jul 15
Jul 15
Buy HIMS on dips as one of author's top-5 preferred names at lower price levels, implying favorable risk/reward at pullback entries.
MED
20:58
Jul 15
Jul 15
Author lists five tickers as top preferences in reply to a parent asking for recovery picks, implying a bullish directional view on each.
20:50
Jul 15
Jul 15
Buy Hims & Hers Health at $20; author's stated add-zone target based on undervaluation, patient entry strategy awaiting bullish market conditions.
MED
15:46
Jul 15
Jul 15
Hims & Hers Health is up over 5% while the broader market declines, but the tweet is a factual price observation without a forward-looking position.
LOW
07:19
Jul 15
Jul 15
No personal directional commitment; lists upcoming catalysts (earnings, FDA meeting) and notes a known bear is buying, but speaker's own stance is absent.
LOW
07:19
Jul 15
Jul 15
Buy HIMS as its distribution platform becomes the default channel for pharma launches; Novo's 89% vs. Lilly's 11% oral obesity Rx share demonstrates that HIMS partnership drives outsized market capture, making HIMS increasingly indispensable as more blockbuster drugs come to market.
MED
00:37
Jul 14
Jul 14
Author discloses a current long position in HIMS, indicating personal conviction in the healthcare stock.
MED
19:08
Jul 13
Jul 13
Buy $IREN and $HIMS at prices below $40, based on the speaker's stated entry threshold.
MED
05:59
Jul 13
Jul 13
The author lists four high-growth tickers but frames them as macro-driven volatile names where long-term thesis matters, not as an active trade call.
LOW
19:00
Jul 12
Jul 12
Author lists HIMS among high-conviction long-term picks and beginner-friendly subscription names, but gives no specific catalyst.
LOW
18:40
Jul 12
Jul 12
Named in a health sector thematic basket the author describes as areas of value they are rotating across.
MED
20:44
Jul 11
Jul 11
Author discloses HIMS as a current core holding (alongside IREN), held since 2023 with a 10x multi-year thesis; no new specific catalyst stated beyond continued conviction in the business fundamentals.
MED
15:21
Jul 09
Jul 09
Hims chart looks like Robinhood fractal.
Hims & Hers chart is forming a similar pattern to Robinhood, suggesting it could go higher.
LOW
12:46
Jul 08
Jul 08
Hims & Hers is a direct-to-consumer telehealth platform using AI for personalization, creating a data flywheel. With a ~$7.9B market cap, the author sees 10x+ upside from continued share gains and AI-
Hims & Hers is a direct-to-consumer telehealth platform using AI for personalization, creating a data flywheel. With a ~$7.9B market cap, the author sees 10x+ upside from continued share gains and AI-driven improvements in outcomes and unit economics.
HIGH
23:22
Jul 07
Jul 07
Author discloses HIMS as one of their current top 5 positions, responding directly to a question about their live holdings.
MED
15:50
Jul 07
Jul 07
Author added to WOLF at $34.3 as it hit his buying target and lists price targets for a basket of stocks he is patient to accumulate.
LOW
21:51
Jul 06
Jul 06
The author increased their position in IREN after reassessing its valuation, drawing a parallel to HIMS' recovery from fear-driven selling and reaffirming their intact thesis.
LOW
21:14
Jul 06
Jul 06
Author reflects on Reddit's recovery and fundamentals while noting capital rotation into hyperscaler bottlenecks, but does not state current positions or forward calls.
16:56
Jul 06
Jul 06
The tweet simply notes that HIMS stock is approaching $40 with an eye emoji, offering no explicit position or forward-looking call.
LOW
10:46
Jul 02
Jul 02
The author draws a parallel between HIMS's past lawsuit-driven selloff and IREN's current sentiment collapse, arguing IREN's strategic power assets and hyperscaler relationships are undervalued as the market prices in only downside.
LOW
10:45
Jul 02
Jul 02
Author draws a parallel between HIMS's lawsuit-driven collapse and recovery and IREN's current sentiment extreme, finding IREN increasingly interesting as a long idea despite acknowledging risks.
LOW
14:15
Jul 01
Jul 01
Buy HIMS under $40 based on the author's long-term thesis that healthcare lacks a platform and HIMS is positioned to fill that gap; current price approaching the stated entry threshold.
MED
12:50
Jul 01
Jul 01
Long HIMS at 5.5% allocation; author added at $18 and remains underwater but maintains conviction, citing strong recent monthly performance and expecting continued positive momentum ahead.
MED
11:00
Jul 01
Jul 01
The tweet presents a historical performance list of retail-favorite stocks for July without any forward-looking position or trade call from the author.
11:56
Jun 30
Jun 30
Speaker presents this as a top pick with bullish catalysts (obesity wave, GLP-1 pivot, chart), no personal position stated.
MED
09:06
Jun 29
Jun 29
The author shares a bullish write-up on HIMS but the parent context expresses skepticism about management, making the endorsement unclear.
23:14
Jun 28
Jun 28
Buy HIMS long-term based on the thesis that healthcare lacks a dominant platform, and Hims & Hers is positioned to fill that gap over the next 5–20 years.
MED
About HIMS Analyst Coverage
Buzzberg tracks HIMS (Hims & Hers Health, Inc.) across 39 sources. 256 bullish vs 33 bearish calls from 54 analysts. Sentiment: predominantly bullish (49%). 455 total trade ideas tracked. Past 7 days: 6 bullish, 6 watch. Latest voices: moninvestor, kaizen_investor, caesarcapitalz.